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Novel pyrano[2,3-d]pyrimidine-2,4,7-triones were synthesized in 90–97% yield via a three-component
reaction of an aromatic aldehyde, Meldrums acid, and barbituric acid in the presence of 10 mol %
K2CO3 under microwave irradiation. This is the ﬁrst protocol to be reported for the synthesis of title com-
pounds and the signiﬁcant features of the present protocol are simplicity, high yields, short reaction time,
involvement of aqueous work-up procedure, environmentally benign nature, and no chromatographic
puriﬁcation.
 2012 Elsevier Ltd. All rights reserved.1,2 25The diversity and interesting biological activities of dihydro-
pyrimidinones (DHPMs) have been explored through the genera-
tion of libraries of compounds via microwave, solid-phase, and
ﬂuorous-phase technologies.2 Pyrimidinone derivatives exhibit
various biological3 and pharmaceutical4 activities such as anti-tu-
mor action; in the treatment of B16 melanoma and P388 leukemia5
or antagonize cell proliferation and induce cell differentiation by
inhibiting (a nontelomeric) endogenous reverse transcriptase.6
Pyrimidine derivatives are very interesting due to their wide range
of biological activities.7 The synthesis of naturally occurring
molecules containing a uracil ring show signiﬁcant synthetic
challenges.8 The development of clinically useful anticancer (5-ﬂu-
orouracil)9 and antiviral drugs (AZT, DDI, BVDU)10–12 has renewed
the interest in the synthetic manipulation of uracils.13 All the com-
pounds which have a uracil moiety in the skeleton of an organic
molecule show antitumor, antibacterial, bronchodilator, vasodila-
tor, antihypertensive, cardiotonic, hepatoprotective, and antialler-
gic activities; some of them also exhibit antimalarial, analgesic,
antifungal, and herbicidal properties.14–21
Multicomponent reactions (MCRs) being highly ﬂexible, selec-
tive, and convergent in nature constitute a signiﬁcant group of
methods in organic synthesis.22 These type of reactions have led
to interesting heterocyclic scaffolds, and are very useful in the con-
struction of diverse chemical libraries of ‘drug-like’ molecules. 23,24
In the last decade microwave irradiation technique has been
utilized as a powerful tool for the various organic transforma-ll rights reserved.
: +91 80 22961331.
).tions. The main beneﬁts of the use of microwave irradiation in-
clude signiﬁcant enhancement of the rate of the reactions,
improvement in the yields, and selectivity.26
As a part of our ongoing research program on the development
of new protocols in the heterocyclic synthesis of biological interest
using readily available, inexpensive, and environment friendly
catalysts,27–33 herein, we report a new, facile, and rapid one-pot
three-component route to the synthesis34 of some novel
5-aryl-5,6-dihydro-1H-pyrano[2,3-d]pyrimidine-2,4,7-triones by
the reaction of aromatic aldehydes, Meldrums acid, and barbituric
acid in the presence of readily available, inexpensive, mild, green,
and common laboratory chemical K2CO3 as the basic catalyst under
neat microwave condition as shown in Scheme 1.
Initially, in order to optimize the reaction conditions, we carried
out the reaction between an aryl aldehyde, Meldrums acid, and bar-
bituric acid in the presence of 10 mol % K2CO3 at different reaction
conditions such as stirring in water at 26 C, at reﬂux, under
ultrasonic irradiation in water; and under solvent-free microwave
irradiation, and found that, no product is formed at room tempera-
ture even after 12 h (Table 1, entry 1). However, at reﬂux only 10%
product formed (entry 2), and the major product was Knoevenagel
condensation product. Under sonication the yield was 20% (entry
3), on heating under neat condition in an oil bath for 1 min there
was no product formation (entry 4), and under the inﬂuence of
microwaves the product was obtained in a very high yield within
1 min (entry 5) and the results of this study are presented in Table 1.
In order to optimize the amount of K2CO3 for the synthesis of
the target compounds, we started the study by treating a mixture
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Scheme 1. Synthesis of 5-aryl-5,6-dihydro-1H-pyrano[2,3-d]pyrimidine-2,4,7-triones.
Table 1
Optimization of the reaction conditions using 10 mol % of K2CO3a as catalyst
Entry Condition Catalyst (mol %) Time (h) Yieldb (%)
1 Silent, water/RT 10 12 ND
2 Water/Reﬂux 10 8 10
3 Water/)))) 10 2 20
4 Heat/neat in oil bath 10 1 min ND
5 MWI 10 1 min 97
a Reactions are performed on a1 mmol scale of all the reactants.
b Isolated yield; ND - not detected.
Table 2
Optimization of the amount of K2CO3a
Entry Catalyst (mol %) Time (min) Yieldb (%)
1 00 6 35
2 5 3 65
3 10 1 97
4 15 2 95
a Reactions are performed on a1 mmol scale of all the reactants.
b Isolated yield.
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der solvent-free condition to get the 5-(40-nitrophenyl)-5,6-dihy-
dro-1H-pyrano[2,3-d]pyrimidine-2,4,7-trione (4a). The results of
this study are summarized in Table 2.
It is noted that, 10 mol % of K2CO3 gave the best result in terms
of time of completion and the product was obtained in 97% yield
(entry 3).
To generalize this methodology, we subjected a series of other
aldehydes having electron-donating as well as electron-withdraw-Table 3
Synthesis of 5-aryl-5,6-dihydro-1H-pyrano[2,3-d]pyrimidine-2,4,7-trione catalyzed by K2C













a All the products are new and were characterized by IR (KBr); 1HNMR; 13CNMR spec
b Isolated yields; ND–not detected.ing substituents to obtain the corresponding 5-aryl-5,6-dihydro-
1H-pyrano[2,3-d]pyrimidine-2,4,7-triones, we also examined the
use of aliphatic aldehydes to get the corresponding products (Table
3 entries 10, 11, and 12) but there was no product formation even
after 4 min of irradiation under the optimized reaction conditions
and the results are presented in Table 3. It can be seen from this
table that, variation in the yields is very little for both electron-rich
and electron-deﬁcient aldehydes. The reactions proceeded to com-
pletion in short durations, and the pure products were obtained
simply by recrystallization from ethanol:acetone (3:2) without
involving any chromatographic puriﬁcation. All the synthesized
compounds are new and were characterized by IR, 1H NMR, 13C
NMR spectral, and elemental analyses.
The formation of the product is expected to involve the forma-
tion of a Knoevenagel adduct 5 by the condensation between 1 and
2; followed by the Michael addition between 3 and 5 to give the
tricyclic intermediate 6. Compound 6 may lose a molecule of ace-
tone to give 7; and 7 may lose a molecule of CO2 to give 8, which
may pick up a proton in the last step to give 5-aryl-5,6-dihydro-
1H-pyrano[2,3-d]pyrimidine-2,4,7-triones (4a–i) as shown in
Scheme 2.
In summary, we have devised a new, simple, and efﬁcient
one-pot three-component protocol for the synthesis of 5-aryl-
5,6-dihydro-1H-pyrano[2,3-d]pyrimidine-2,4,7-trione derivatives
using K2CO3 as a mild, readily available, inexpensive, and efﬁcient
catalyst under neat condition in a microwave reactor at 250W.
The advantages offered by this method are: simple reaction
condition, short reaction time, ease of product isolation, and
excellent yields. We wish to state that this method involves
an environment friendly procedure, and is the ﬁrst procedure
for the synthesis of novel H-pyrano[2,3-d]pyrimidine-2,4,7-triones.O3 under microwave irradiation































































































Scheme 2. A plausible mechanism for the formation of 5-aryl-5,6-dihydro-1H-pyrano[2,3-d]pyrimidine-2,4,7-triones.
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218–220 C; IR (KBr): m 3413 (s), 3293(w), 2983 (s), 1727 (s), 1687 (vs), 1589
(vs), 1524 (s), 1447 (s), 1361 (vs), 1289 (s), 1173 (s), 1040 (s) cm1; 1HNMR
(400 MHz, DMSO-d6): d 3.35 (d, J = 6.8 Hz, 2H, CH2), 4.47 (t, J = 7.2 Hz, 1H, CH),
7.22–7.29 (m, 2H, Ph), 7.41–7.46 (m, 2H, Ph), 11.24 (s, 1H, NH), 11.41 (s, 1H,
NH); 13CNMR (100 MHz, DMSO-d6): d 165.1 (O–C@O), 161.9 (NH–CO–C@C
pyrimidine), 150.8 (NH–CO–NH pyrimidine), 151.6 (NH–C@C–C pyrimidine),
147.2, 138.5, 131.5, 130.4, 126.9, 124.1 (all ArCs), 91.0 (C–C@C–NH
pyrimidine), 30.0 (CH2), 24.0 (CH). Anal. Calcd for C13H9N3O6: C, 51.49; H,
2.99; N, 13.86%. Found: C, 51.48; H, 2.98; N, 13.85%.5-(20-chlorophenyl)-5,6-
dihydro-1H-pyrano[2,3-d]pyrimidine-2,4,7-trione (4d): Mp 240 C; IR (KBr): m
3408 (s), 3298 (w), 2978 (s), 1738 (s), 1694 (vs), 1589 (vs), 1516 (s), 1465 (s),
1347 (vs), 1276 (s), 1173 (s), 1033 (s), 746 (s) cm1; 1HNMR (400 MHz, DMSO-
d6): d 3.35 (d, J = 7.2 Hz, 2H, CH2), 4.39 (t, J = 7.2 Hz, 1H, CH), 7.06–7.15 (m, 2H,Ph), 7.19–7.27 (m, 2H, Ph), 11.23 (s, 1H, NH), 11.43 (s, 1H, NH); 13CNMR
(100 MHz, DMSO-d6): d 165.3 (O–C@O), 161.7 (NH–CO–C@C pyrimidine), 151.6
(NH–CO–NH pyrimidine), 154.9 (NH-C@C–C pyrimidine), 143.2, 133.6, 131.1,
130.0, 127.3, 126.4 (all ArCs), 91.0 (C–C@C–NH pyrimidine), 31.6 (CH2), 24.8
(CH). Anal. Calcd for C13H9ClN2O4: C, 53.35; H, 3.10; N, 9.57%. Found: C, 53.34;
H, 3.10; N, 9.55%.5-(20 ,40-dimethoxyphenyl)-5,6-dihydro-1H-pyrano[2,3-
d]pyrimidine-2,4,7-trione (4e): Mp 235–237 C; IR (KBr): m 3404 (s), 3298 (w),
2989 (s), 1720 (vs), 1694 (s), 1583 (vs), 1498 (s), 1447 (s), 1367 (s), 1269 (vs),
1173 (s), 1030 (s) cm1; 1HNMR (400 MHz, DMSO-d6): d 3.33 (d, J = 10.8 Hz,
2H, CH2), 3.89 (s, 3H, OCH3), 3.92 (s, 3H,OCH3), 4.57 (t, J = 7.2 Hz, 1H, CH), 6.65–
6.68 (d, J = 11.2 Hz,1H, Ph), 7.21–7.23 (d, J = 8.4 Hz, 1H, Ph), 7.58 (s, 1H, Ph)
11.04 (s, 1H, NH), 11.18 (s, 1H, NH); 13CNMR (100 MHz, DMSO-d6): d 164.9 (O–
C@O), 163.5 (NH–CO–C@C pyrimidine), 151.3 (NH–CO–NH pyrimidine), 152.3
(NH–C@C–C pyrimidine), 144.6, 135.6, 129.1, 114.6, 107.5, 104.9 (all ArCs),
91.6 (C–C@C–NH pyrimidine), 57.2(OCH3), 56.8 (OCH3), 27.7 (CH2), 20.5 (CH).
Anal. Calcd for C15H14N2O6: C, 56.60; H, 4.43; N, 8.80%. Found: C, 56.58; H,
4.421; N, 8.80%.5-(40-ﬂorophenyl)-5,6-dihydro-1H-pyrano[2,3-d]pyrimidine-
2,4,7-trione (4f): Mp 266 C; IR (KBr): m 3417 (w), 3295 (w), 2959 (s), 1734
(s), 1694 (vs), 1583 (vs), 1504 (s), 1447 (s), 1347 (vs), 1249 (s), 1034 (s) cm1;
1HNMR (400 MHz, DMSO-d6): d 3.33 (d, J = 7.6 Hz, 2H, CH2), 4.39 (t, J = 7.2 Hz,
1H, CH), 7.42–7.48 (dd, J1 = 8.8 Hz, J1 = 7.2 Hz, 2H, Ph), 7.98–8.02 (dd,
J1 = 5.6 Hz, J1 = 6.0, 2H, Ph), 11.19 (s, 1H, NH), 11.41 (s, 1H, NH); 13CNMR
(100 MHz, DMSO-d6): d 170.0 (O–C@O), 163.5 (NH–CO–C@C pyrimidine), 151.5
(NH–CO–NH pyrimidine), 154.6 (NH–C@C–C pyrimidine), 159.6, 133.2, 129.2,
129.1, 117.4, 117.2 (all ArCs), 91.9 (C–C@C–NH pyrimidine), 30.9 (CH2), 26.4
(CH); Anal. Calcd for C13H9FN2O4: C, 56.53; H, 3.28; N, 10.14%. Found: C, 56.53;
H, 3.27; N, 10.15%.5-(30-nitrophenyl)-5,6-dihydro-1H-pyrano[2,3-d]pyrimidine-
2,4,7-trione (4g): Mp 273 C; IR (KBr): m 3391 (s), 3291(w), 2959 (w), 1724 (s),
1699 (vs), 1589 (vs), 1527 (s), 1447 (s), 1339 (vs), 1200 (s), 1173 (w), 1020 (s)
cm1; 1HNMR (400 MHz, DMSO-d6): d 3.34 (d, J = 8.0 Hz, 2H, CH2), 4.47 (t,
J = 7.2 Hz, 1H, CH), 6.95 (s, 1H, Ph), 7.47 (d, J = 5.2 Hz,1H, Ph), 7.81 (d,
J = 4.8 Hz,1H, Ph), 7.94–7.97(t, J = 5.6 Hz, 1H, Ph), 10.15 (s, 1H, NH), 11.14 (s,
1H, NH); 13CNMR (100 MHz, DMSO-d6): d 168.7 (O–C@O), 164.6 (NH–CO–C@C
pyrimidine), 153.5 (NH–CO–NH pyrimidine), 156.7 (NH–CO–C@O C–C
pyrimidine), 147.6, 140.4, 131.6, 128.8, 122.7, 118.6 (all ArCs), 91.6 (C–C@C–
NH pyrimidine), 34.7 (CH2), 23.0 (CH); Anal. Calcd for C13H9N3O6: C, 51.49; H,
2.99; N, 13.86%. Found: C, 51.48; H, 2.99; N, 13.85%.5-(4’-chlorophenyl)-5,6-
dihydro-1H-pyrano[2,3-d]pyrimidine-2,4,7-trione (4h): Mp 282 C; IR (KBr): m
3394 (s), 3291(w), 2959 (s), 1738 (s), 1681 (s), 1589 (w), 1524 (s), 1447 (w),
1354 (vs), 1216 (s), 1173 (w), 1010 (s), 746 (s) cm1; 1HNMR (400 MHz, DMSO-
d6): d 3.46 (d, J = 7.2 Hz, 2H, CH2), 4.39 (t, J = 7.2 Hz, 1H, CH), 7.00–7.02
(d, J = 8.8 Hz, 2H, Ph), 7.87–7.89 (d, J = 8.4 Hz, 2H, Ph), 11.23 (s, 1H, NH), 11.43
(s, 1H, NH); 13CNMR (100 MHz, DMSO-d6): d 168.6 (O–C@O), 162.5 (NH–CO–
C@C pyrimidine), 152.5 (NH–CO–NH pyrimidine), 157.6 (NH–C@C–C
pyrimidine), 148.7, 135.5, 127.8, 126.6, 119.9, 118.0 (all ArCs), 92.7 (C–C@C–
NH pyrimidine), 32.2 (CH2), 22.4 (CH). Anal. Calcd for C13H9ClN2O4: C, 53.35; H,
3.10; N, 9.57%. Found: C, 53.34; H, 3.11; N, 9.55%.5-(30 ,40-dimethoxyphenyl)-5,6-
dihydro-1H-pyrano[2,3-d]pyrimidine-2,4,7-trione (4i): Mp 277 C; IR (KBr): m
3404 (s), 3288 (w), 2969 (s), 1730 (s), 1694 (s), 1589 (s), 1504 (s), 1447 (w),
1340 (s), 1276 (vs), 1173 (s), 1040 (s) cm1; 1HNMR (400 MHz, DMSO-d6),
d 3.34 (d, J = 8.0 Hz, 2H, CH2), 3.80 (s, 3H, OCH3), 3.88 (s, 3H, OCH3), 4.39
(t, J = 7.2 Hz, 1H, CH), 7.09 (d, J = 8.8 Hz, 1H, Ph), 7.88–7.90 (d, J = 8.4 Hz, 1H,
Ph), 8.24 (s, 1H, Ph), 11.19 (s, 1H, NH), 11.31 (s, 1H, NH); 13CNMR (100 MHz,
DMSO-d6): d 164.9 (O–C@O), 163.2 (NH–CO–C@C pyrimidine), 154.5 (NH-CO-
NH pyrimidine), 156.3 (NH-C@C–C pyrimidine), 151.1, 148.6, 132.6, 126.1,
117.6, 116.1 (all ArCs), 91.4 (C–C@C–NH pyrimidine), 56.7(OCH3), 56.3 (OCH3),
31.9 (CH2), 24.8 (CH). Anal. Calcd for C15H14N2O6: C, 56.60; H, 4.43; N, 8.80%.
Found: C, 56.60; H, 4.43; N, 8.79%.
